Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB05271_nanopub.RA6-dsa8mznZtfEEkaVFqrjP2VmE5K2PQd1PlvAo7ev_A#assertion>. }
Showing items 1 to 25 of
25
with 100 items per page.
- drugbank:DB05271 type drugbank_vocabulary:Drug assertion.
- drugbank:DB05271 label "Rotigotine [drugbank:DB05271]" assertion.
- drugbank:DB05271 seeAlso DB05271 assertion.
- drugbank:DB05271 seeAlso rotigotine-transdermal.html assertion.
- drugbank:DB05271 seeAlso neupro-drug.htm assertion.
- drugbank:DB05271 identifier "drugbank:DB05271" assertion.
- drugbank:DB05271 description "Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours. Like other dopamine agonists, rotigotine has been shown to possess antidepressant effects and may be useful in the treatment of depression as well. Rotigotine was developed by Aderis Pharmaceuticals. In 1998, Aderis licensed worldwide development and commercialization rights for rotigotine to the German pharmaceutical company Schwarz Pharma (today a subsidiary of the Belgian company UCB S.A.). The drug has been approved by the EMEA for use in Europe in 2006 and is today being sold in several European countries. In 2007, the Neupro patch was approved by the Food and Drug Administration (FDA) as the first transdermal treatment of Parkinson's disease in the United States. However, as of 2008, Schwarz Pharma has recalled all Neupro patches in the United States and some in Europe because of problems with the delivery mechanism. Rotigotine has been authorized as a treatment for RLS since August 2008." assertion.
- drugbank:DB05271 title "Rotigotine" assertion.
- drugbank:DB05271 bio2rdf_vocabulary:identifier "DB05271" assertion.
- drugbank:DB05271 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB05271 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB05271" assertion.
- drugbank:DB05271 bio2rdf_vocabulary:x-identifiers.org DB05271 assertion.
- drugbank:DB05271 drugbank_vocabulary:drugbank-id "DB05271" assertion.
- drugbank:DB05271 drugbank_vocabulary:x-cas cas:92206-54-7 assertion.
- drugbank:DB05271 drugbank_vocabulary:x-chemspider chemspider:51867 assertion.
- drugbank:DB05271 drugbank_vocabulary:x-pubchemcompound pubchem.compound:57537 assertion.
- drugbank:DB05271 drugbank_vocabulary:x-pubchemsubstance pubchem.substance:99443232 assertion.
- drugbank:DB05271 drugbank_vocabulary:x-atc atc:N04BC09 assertion.
- drugbank:DB05271 drugbank_vocabulary:x-kegg kegg:D05768 assertion.
- drugbank:DB05271 drugbank_vocabulary:x-pharmgkb pharmgkb:PA165958352 assertion.
- drugbank:DB05271 drugbank_vocabulary:x-wikipedia wikipedia:Rotigotine assertion.
- drugbank:DB05271 drugbank_vocabulary:x-bindingdb bindingdb:50054062 assertion.
- drugbank:DB05271 drugbank_vocabulary:x-ndc ndc:50474-801-03 assertion.
- drugbank:DB05271 drugbank_vocabulary:x-gtp gtp:941 assertion.
- drugbank:DB05271 drugbank_vocabulary:x-iuphar iuphar:941 assertion.